Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Associated Foot & Ankle Specialists has started recruiting patients with foot ulcers due to diabetes to participate in the Matrix clinical trial to evaluate the effects of a new product, Excellarate.
Subscribe to our email newsletter
The trial is a randomized, double-blind safety and efficacy research study in which Excellarate is topically administered once or twice over the course of the study, with a goal of complete ulcer closure at 12 weeks or earlier.
Arthur Tallis, podiatric physician & surgeon at Associated Foot & Ankle Specialists and a trial investigator, said: “The Excellarate topical gel, using Gene Activated Matrix (GAM) technology is designed to provide release of the platelet-derived growth factor BB protein, which stimulates angiogenesis (the growth of new blood vessels) and granulation tissue formation, the building blocks for a variety of wound healing processes.”